This implies that the duration of our therapy and the availability of antibodies are the only factors limiting the long-term tumor-suppressive efficacy of fibulin-3 inhibition in PM cells, even in cell types that secrete high levels of this protein [27]. The gene discussed is EFEMP1; the disease is neoplasm.